Clinical trials: Ovarian Epithelial Cancer
Prostate Cancer, Breast Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
This study will determine the best doses of docetaxel and lonafarnib when the two anti-cancer agents are used in combination. Patients with tumors for which treatment with docetaxel would be appropriate are eligible.
- Conditions
- Prostate Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer
- Trial name
- NCT00539968
- Testing
- Docetaxel plus lonafarnib
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are…
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06451497
- Testing
- ZM008
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Zumutor Biologics Inc.
Colorectal Cancer (CRC), Pancreatic Cancer
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency.
- Conditions
- Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC)
- Trial name
- NCT06751524
- Testing
- Botensilimab, Balstililmab
- Sponsor
- Agenus Inc.
Breast Cancer, Colorectal Cancer
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human antibody.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT04244552
- Testing
- ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
- Where
- 19 sites in United States
- Volunteers
- 87 people
- Sponsor
- Atreca, Inc.
Ovarian Cancer
Trial of THEO-260 in Ovarian Cancer Patients
A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well…
- Trial name
- OCTOPOD (NCT06618235)
- Testing
- THEO-260
- Where
- 4 sites in Spain, United Kingdom
- Volunteers
- 44 people
- Sponsor
- Theolytics Limited
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Pancreatic Adenocarcinoma, Ovarian Cancer
Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning.
- Conditions
- Pancreatic Adenocarcinoma, Ovarian Cancer, Biliary Carcinoma, Colorectal Cancer
- Trial name
- NCT03225989
- Testing
- LOAd703
- Where
- 2 sites in Sweden
- Volunteers
- 47 people
- Sponsor
- Lokon Pharma AB
Malignant Solid Tumors, Lymphoma
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.
- Conditions
- Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03205176
- Testing
- AZD5153, Olaparib
- Where
- 4 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Advanced Breast Carcinoma, Advanced Ovarian Carcinoma
Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
This is a two-part Phase 1b, open-label study of ONT 10 administered in combination with varlilumab. Two different doses of varlilumab will be studied in combination with the single agent recommended dose of ONT 10.
- Trial name
- NCT02270372
- Testing
- ONT-10, Varlilumab combination
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Cascadian Therapeutics Inc.
Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer
EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP).
- Conditions
- Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma
- Trial name
- EPITOME-1015-I (NCT06748872)
- Testing
- Lymphodepletion, TCR-T cells (MDG1015)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Medigene AG
Solid Tumor, Adult, Carcinoma, Ovarian Epithelial
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD)…
- Conditions
- Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer
- Trial name
- NCT04196257
- Testing
- BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Bio-Path Holdings, Inc.
Platinum-resistant Ovarian Cancer, Platinum-resistant Primary Peritoneal Cancer
A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
This is a randomized, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of SYS6043 versus investigator's choice chemotherapy in participants with platinum-resistant ovarian cancer…
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-resistant Primary Peritoneal Cancer, Platinum-resistant Fallopian Tube Cancer
- Trial name
- NCT07708753
- Testing
- SYS6043, Liposomal doxorubicin, paclitaxel, or topotecan
- Where
- China
- Volunteers
- 460 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Ovarian Cancer, Ovarian Neoplasms
A Trial of Vigil for Participants With Ovarian Cancer
The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated with investigational product (Vigil) compared to placebo.
- Trial name
- VITAL (NCT02346747)
- Testing
- Vigil
- Where
- 26 sites in United States
- Volunteers
- 92 people
- Sponsor
- Gradalis, Inc.
Advanced Ovarian Cancer
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
The purpose of this study is to evaluate the optimal dose of 2X-121 as single agent therapy at 600 mg daily (split BID 200 mg morning + 400 mg evening) compared to 800 mg daily (split BID 400 mg morning + 400 mg evening) in…
- Trial name
- NCT03878849
- Testing
- 2X-121
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Allarity Therapeutics
Ovarian Neoplasms
Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer
Primary objective: To assess response rate. To record the clinical improvement in relation to stage and histopathological grading. Secondary objective: To determine progression free survival. To find out overall survival.
- Trial name
- OCSTUD (NCT00452985)
- Testing
- Docetaxel, Carboplatin
- Where
- Bangladesh
- Volunteers
- 30 people
- Sponsor
- Sanofi
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
The purpose of this study is to evaluate the safety and efficacy of BG-C9074 with bevacizumab (Arm A) versus bevacizumab monotherapy (Arm B) in adults with epithelial ovarian, fallopian tube, or primary peritoneal cancers who…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07811271
- Testing
- BG-C9074, Bevacizumab
- Volunteers
- 600 people
- Sponsor
- BeOne Medicines
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Platinum-resistant Recurrent Ovarian Cancer (PROC)
A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.
A Phase 1, single-arm, single-center, open-label, prospective, dose-escalation, and cohort expansion study to assess the safety, tolerability, pharmacokinetic (PK), and preliminary efficacy of WSK-IM02 administered as a single…
- Trial name
- NCT07462468
- Testing
- WSK-IM02
- Volunteers
- 36 people
- Sponsor
- WestVac Biopharma Co., Ltd.
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.